ArticleFrontiers in immunology2026
Perioperative PD-1 inhibitor plus chemotherapy versus chemotherapy alone in gastric cancer with PAN metastasis undergoing D2 gastrectomy and PAND: a single-center retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Research on the efficacy of perioperative immunotherapy for gastric cancer with para-aortic lymph node (PAN) metastasis remains limited. This study aimed to compare the safety and efficacy of chemotherapy plus programmed cell death protein-1 (PD-1) inhibitor versus chemotherapy alone in locally advanced GC patients with PAN metastasis. Methods: We retrospectively reviewed patients with gastric cancer and limited No.16a2/b1 lymph node metastasis who received perioperative systemic therapy combined with D2 gastrectomy plus PAN dissection (PAND) between January 2018 and February 2024. Patients were divided into Group A (chemotherapy+PD-1 inhibitor, n=62) and Group B (chemotherapy alone, n=71). Pathological response, survival outcomes, and safety were evaluated. Results: All patients in Group A achieved R0 resection, compared with 98.6% in Group B. Pathological outcomes were significantly better in Group A, with higher rates of pathological complete response (pCR; 37.1% vs. 4.2%, P<0.001) and major pathological response (MPR; 58.1% vs. 22.5%, P<0.001) compared to Group B. In Group A, patients with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥5 had higher pCR rates. The 3-year overall survival (OS) rate was also higher in Group A (64.5% vs. 42.3%). The median OS for Group B was 33.2 months, while Group A was not reached (P = 0.023). Adverse event incidences were comparable between groups, with no treatment-related deaths. Conclusion: Perioperative immunochemotherapy significantly enhances pathological response and survival in GC patients with PAN metastasis, with manageable safety. This regimen represents a promising therapeutic strategy for this patient population, necessitating long-term follow-up to confirm durable benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.